Clinical Trials

470 enrolled

Urinary Bladder Neoplasms

NCT04628767 2026-04-14

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

249 enrolled

Renal Pelvis and Ureter Urothelial Carcinoma

NCT05139017 2026-04-07

waveLINE-003

290 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT02135042 2026-04-03

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

685 enrolled

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT06926868 2026-04-01

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

500 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07076121 2026-03-31

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

470 enrolled

Pancreatic Neoplasms

NCT04559139 2026-03-19

Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer

186 enrolled

Gallbladder Neoplasms

NCT07129993 2026-03-19

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

630 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03178552 2026-03-09

B-FAST

1,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07366840 2026-01-26

BRIGHT

268 enrolled

Breast Neoplasms

NCT06115499 2026-01-07

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

10 enrolled

Pancreatic Neoplasms

NCT06361888 2025-12-30

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

502 enrolled

Pancreatic Neoplasms

NCT06783140 2025-12-05

PLATINUM-CAN

10 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms

NCT04442022 2025-10-03

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

501 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05870748 2025-09-23

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

600 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05096663 2025-05-15

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

82 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06214572 2025-04-11

RUGB

249 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT06923475 2025-04-11

NEODISCO

150 enrolled

Cholangiocarcinoma, Klatskin Tumor

NCT06493552 2025-04-03

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

700 enrolled

Carcinoma, Transitional Cell

NCT02867865 2025-03-13

POLCAGB

124 enrolled

Gallbladder Neoplasms

NCT06037980 2025-02-17

PURITY

300 enrolled

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT03366272 2025-01-28

NIVEAU

348 enrolled

Lymphoma, Non-Hodgkin

NCT03512756 2024-11-06

A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer

130 enrolled 13 charts

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT05254171 2024-11-06

ASPIRE

600 enrolled

Pancreatic Neoplasms

NCT03721744 2024-04-03

A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer

336 enrolled

Pancreatic Neoplasms

NCT06268327 2024-02-20

Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy

30 enrolled

Breast Neoplasms

NCT02641847 2024-01-25

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

503 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05576272 2023-11-22

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

460 enrolled

Nasopharyngeal Carcinoma

NCT04066491 2023-11-14

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

309 enrolled 17 charts

Biliary Tract Neoplasms, Camurati-Engelmann Syndrome, Gallbladder Neoplasms, Cholangiocarcinoma

NCT00385606 2023-03-23

Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC

400 enrolled

Advanced Non-small Cell Lung Cancer

NCT00997906 2022-09-29

Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC

172 enrolled

Head and Neck Neoplasms

NCT03674242 2022-08-01

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)

27 enrolled

Triple Negative Breast Neoplasms

NCT04037241 2022-04-01

Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases

Phase 2/3 Withdrawn

Malignant Tumor of Pancreas Metastatic to Liver

NCT03086993 2022-03-24

Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma

295 enrolled

Bile Duct Neoplasms, Cholangiocarcinoma

NCT04890522 2021-05-18

An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC

622 enrolled

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT01438112 2021-04-14

BOND

22 enrolled

Adenoviridae Infections, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Virus Diseases

NCT00112658 2021-03-08

Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

342 enrolled

Pancreatic Neoplasms

NCT02490488 2020-12-08

Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients

248 enrolled

Gynecologic

Ovarian Neoplasms

NCT02172976 2020-09-02

Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma

40 enrolled

Pancreatic Neoplasms

NCT01774578 2020-05-28

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

135 enrolled

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

111 enrolled 20 charts

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01631357 2019-11-05

CIK

96 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

NCT03610100 2019-10-29

ACELARATE

Phase 2/3 Suspended

328 enrolled

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT02240017 2019-08-09

VEFORA

46 enrolled

Advanced Urothelial Cancer

NCT02527772 2019-06-04

LD-FOX4/HCC

Phase 2/3 Withdrawn

Carcinoma, Hepatocellular

NCT02534337 2019-06-04

Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma

Phase 2/3 Withdrawn

Carcinoma, Hepatocellular

NCT01881230 2019-02-21

tnAcity

191 enrolled 22 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01407822 2018-09-11

EMERGING

72 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03423849 2018-02-06

The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy

200 enrolled